KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:开放图源暂不可得 入排置信度 0.98

Efficacy of vunakizumab in patients with moderate-to-severe plaque psoriasis across diverse disease features: a post hoc analysis of a phase-III trial.

Jingjing Liu, Junyi Shao, Liyue Hou, Enci Mei, Lili He, Jingying Wang, Anqi Chen, Yi Zhang, Zhiming Li

J Dermatolog Treat 37(1) 2641340

PMID42333837
PMCID-
DOI10.1080/09546634.2026.2641340
发表日期2026-06-23
入排依据:未发现恶性肿瘤人群证据。
PubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。
摘要

摘要

BACKGROUND: The efficacy of interleukin-17 inhibitors may be impacted by baseline psoriasis features. OBJECTIVE: This post hoc analysis aimed to explore the efficacy of vunakizumab in patients with moderate-to-severe plaque psoriasis stratified by diverse disease features. METHODS: This post hoc analysis used data from a phase III trial (NCT04839016); 690 patients with moderate-to-severe plaque psoriasis receiving vunakizumab (n = 461) or placebo (n = 229) were included. RESULTS: The proportions of patients achieving Psoriasis Area and Severity Index (PASI) 75, PASI 90, PASI 100, and static physician's global assessment (sPGA) 0/1 responses at week (W)12 were significantly higher in the vunakizumab group than in the placebo group, regardless of the duration of psoriasis, PASI score, body surface area (BSA) involvement, and sPGA score. Similarly, at W4 and W8, treatment response rates were higher in the vunakizumab group than in the placebo group, regardless of the above-mentioned features. The same trend was also found at W24. However, treatment responses at W52 were almost not different between patients continuously receiving vunakizumab and those switching from placebo to vunakizumab, regardless of disease duration and disease severity. CONCLUSION: Vunakizumab shows satisfactory efficacy in patients with moderate-to-severe plaque psoriasis, regardless of psoriasis duration and severity.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。